Clinical trial · Observational
Circulating Tumor DNA in Patients at High Risk for Lung Cancer
Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for Detection of Lung Cancer in Patients Undergoing Diagnostic or Therapeutic Bronchoscopy or Thoracotomy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Patient accrual was slow due to exclusion of patients with prior cancers
Summary
Brief summary (as posted)
Patients who are about to undergo a diagnostic or therapeutic bronchoscopy or thoracic surgery without a distant history of cancer will have their blood drawn for measurement of circulating tumor DNA (ctDNA) to validate the utility of molecular diagnostic assays for the early detection of lung cancer.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of the Lung | Lung Adenocarcinoma | ALIAS | 0.90 |
| Cancer of the Lung | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Non Small Cell Carcinoma of the Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Small Cell Carcinoma of the Lung | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Percentage of patients with lung cancer who had a positive ctDNA result (true positive)
- timeFrame
- 5 years
- description
- ctDNA results will be correlated with pathology and subsequent clinical findings.
Secondary outcomes (4)
- measure
- Percentage of patients who develop any cancer during the 5 years of follow-up
- timeFrame
- 5 years
- description
- ctDNA results will be correlated with pathology and subsequent clinical findings.
- measure
- Percentage of patients without lung cancer who had a positive ctDNA result (false positive)
- timeFrame
- 5 years
- description
- ctDNA results will be correlated with pathology and subsequent clinical findings.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older, not previously diagnosed with cancer (except for basal cell carcinomas of the skin or a diagnosis of cancer within a month of surgery and for which the surgical procedure is being performed). Exclusion Criteria: * Prior history of cancer.
References
Publications (0)
Data not yet available